AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome.
Muscle Research Laboratory, Mayo Clinic, Rochester, Minnesota 55905, USA.
T
T
Fukudome
K
K
Ohno
J M
JM
Brengman
A G
AG
Engel
D002460:Cell Line; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology; D009157:Myasthenia Gravis / Q000151:congenital / Q000503:physiopathology*; D017354:Point Mutation; D011802:Quinidine / Q000494:pharmacology*; D011950:Receptors, Cholinergic / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism; D013577:Syndrome; D014162:Transfection
D018680:Cholinergic Antagonists; D011950:Receptors, Cholinergic; D011994:Recombinant Proteins; D011802:Quinidine